                </a></li></ul></div><p><strong>Figure 8.  <span>Treatment protocol of HB1.F3.C1/AdCMVrCE/CPT-11 NDEPT.</span></strong></p><a id="article1.body1.sec2.sec9.fig8.caption1.p1" name="article1.body1.sec2.sec9.fig8.caption1.p1"></a><p>One day prior to being used in treatments, cells were transduced with the AdCMVrCE construct (see text).</p>
<a id="article1.body1.sec2.sec9.fig8.caption1.p2" name="article1.body1.sec2.sec9.fig8.caption1.p2"></a><p>The treatment schedule was based on the time-course of expression of the secreted form of rCE, following adenoviral transduction of HB1.F3.C1 cells (Danks, unpublished observation) and on a schedule of administration of CPT-11 that has been shown to be relatively effective for neuroblastoma patients <a href="#pone.0000023-Furman1">[35]</a>.</p>
<span>THISISTHEEND
